ED Injections vs. Oral Medication: Pros, Cons, and When Each Makes Sense

Short answer: oral PDE5 inhibitors are the right first step for most men. Injection therapy (alprostadil) is the evidence-backed second line when pills fail — especially after nerve injury — but higher discontinuation rates reflect the invasiveness tradeoff.

Oral medication is the default starting point for ED treatment, and for good reason — it's simple and effective for most men. But it doesn't work for everyone, and injection therapy exists specifically to fill that gap. Here's how the two actually compare.

Why Oral Medication Doesn't Work for Some Men

Oral PDE5 inhibitors like sildenafil have a built-in dependency: they require sexual stimulation to trigger nitric oxide release before the drug can do anything — without arousal, there's no effect.^[1]That's part of why the FDA label recommends taking sildenafil about an hour before activity (within a 30-minute to 4-hour window), and why clinical trials showed 63% to 82% of patients (depending on dose) reported improved erections, versus 24% on placebo.^[1]

That stimulation-dependent mechanism is exactly where oral medication runs into trouble for some men: a peer-reviewed study found roughly 30–35% of patients don't respond to PDE5 inhibitors at all, and intracavernosal vasoactive agents like alprostadil are the standard second-line approach for that group.^[3] Injection therapy sidesteps the whole nitric oxide pathway — alprostadil is injected directly into the corpus cavernosum, where it binds prostaglandin receptors and triggers smooth muscle relaxation independently, which is why it can work even in men whose underlying nerve or nitric oxide signaling has been damaged.^[2]

How Effective Is Injection Therapy?

The FDA label for Caverject reports over 80% of patients in clinical trials achieved an erection sufficient for intercourse — and this wasn't limited to men who'd already failed oral therapy.^[2] Real-world data backs this up: the label documents 73% of injections among 102 men self-administering at home resulted in satisfactory intercourse, and across a larger cohort of 13,762 injections, 87% resulted in satisfactory sexual activity.^[7] The original 1996 pivotal trial in the New England Journal of Medicine — 683 men over six months of self-injection — found participants were able to have sexual activity after 94% of injections, concluding the therapy was effective and tolerable even in men whose ED had multiple underlying causes.^[5]

Speed and Duration Work Differently for Each

Injection therapy is notably faster: the Caverject label puts onset at 5 to 20 minutes, compared to roughly 30 minutes to 2 hours for sildenafil.^[2] That speed comes with a built-in ceiling, though — the treatment goal for injection is an erection lasting no longer than an hour, with an average recorded duration of 70.8 minutes in clinical trials.^[4] Oral medication offers a longer usable window by comparison — up to 4 hours for sildenafil, or up to 36 hours for tadalafil.

The Real Tradeoff: Invasiveness

This is where the two approaches diverge most in practice. Oral medication requires swallowing a pill. Injection therapy requires learning a specific self-injection technique and administering medication directly into the side of the penis before each use.^[6] That difference has a measurable real-world consequence: dropout rates from injection therapy vary widely across studies, from 4.9% to 64.3%, and one study found 79.9% of patients had discontinued by their last follow-up — with poor response (43.1%) and inconvenience (18.3%) cited as the top two reasons.^[6]

Different Side-Effect Profiles

Because injection therapy acts locally rather than systemically, it carries a different risk profile than oral medication. The Caverject label reports prolonged erection (4 to 6 hours) in 4% of patients and priapism (6+ hours, requiring urgent care) in 0.4%.^[2]Oral PDE5 inhibitors instead carry systemic effects — sildenafil's label lists headache (16–28%), flushing (10–19%), dyspepsia (3–17%), and abnormal vision (up to 11% at the highest dose) as the most common reactions, none of which apply to injection therapy since it doesn't circulate systemically.^[1]That same systemic action is why oral PDE5 inhibitors carry an absolute nitrate contraindication that alprostadil doesn't share — alprostadil works locally within the penis rather than through the same systemic vasodilation pathway.^[1]

The Bottom Line

For most men, oral medication is the right starting point — it's effective, simple, and non-invasive. Injection therapy exists for the meaningful minority who don't respond to pills, particularly men with nerve-related ED (like after prostatectomy) where the oral mechanism can't engage at all. It works fast and works well when it works — the real cost is the injection itself, which is why discontinuation rates run high even among men for whom it's effective.

If oral medication hasn't worked for you, ask a provider whether injection therapy is a reasonable next step — or compare Men's Health options on RENVA's hub rather than assuming you've exhausted your options.

Frequently Asked Questions